Skip to main content

Thermo Fisher Scientific Value Stock - Dividend - Research Selection

Thermo fisher scientific

ISIN: US8835561023 , WKN: 857209

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide. Its Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of new drugs and vaccines, as well as diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment offers instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and research and industrial markets, as well as clinical laboratories. Its Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; blood-test systems; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; products for cancer diagnosis and medical research in histology, cytology, and hematology; human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel products. This segment serves healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Its Laboratory Products and Services segment offers laboratory refrigerators and freezers, ultralow-temperature freezers and cryopreservation storage tanks, temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis and laboratory equipment; laboratory plastics; laboratory chemicals; research and safety market channel; and pharma services. The company was founded in 1956 and is headquartered in Waltham, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel

2026-10-02
QGEN expands its U.S. QIAstat-Dx portfolio with an FDA-cleared panel that detects gram-negative bacteria and resistance markers in about one hour.

Cell and Gene Therapy Bio-Manufacturing Market Global Report 2026: Market to Surge to $21.46 Billion by 2030 as Thermo Fisher Scientific, Merck KGaA, Lonza and Samsung Biologics Accelerate Automation

2026-10-01
Boost ROI with scalable viral-vector platforms, automated single-use processing, digital quality control, and expanded CDMO capacity through partnerships and acquisitions.Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- "Cell and Gene Therapy Bio-Manufacturing Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global cell and gene therapy biomanufacturing market is experiencing rapid expansion as advanced therapies move from research and clinical development toward comm

Biomarkers Market Forecasts Growth from $67.95B (2026) to $112.10B by 2031, Profiling Roche, Abbott, Thermo Fisher & Qiagen

2026-10-01
The global biomarkers market is projected to grow from USD 67.95 billion in 2026 to USD 112.10 billion by 2031, registering a 10.5% CAGR. Growth is driven by precision medicine, companion diagnostics, AI, bioinformatics, digital pathology and multi-omics technologies. Predictive biomarkers led the efficacy segment in 2025, while immunoassays held the largest technology share. Asia Pacific is forecast to be the fastest-growing region. Key players include Roche, Abbott, Thermo Fisher Scientific, Q

Radiation Detection, Monitoring & Safety Market Forecasts Growth from $3.80B (2026) to $5.68B by 2031, Profiling Fortive, Thermo Fisher & Mirion Technologies

2026-10-01
The global radiation detection, monitoring & safety market is projected to grow from USD 3.80 billion in 2026 to USD 5.68 billion by 2031, at an 8.4% CAGR. Growth is driven by expanding medical imaging and radiotherapy, nuclear energy investments, regulatory requirements, and security concerns. Detection and monitoring products and radiation detectors lead the market, while Asia Pacific is set for significant growth. Key players include Fortive, Thermo Fisher Scientific, Mirion Technologies, Fuj

The Top HealthTech Questions Landing On Our Desks

2026-10-01
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation.

Recombinant Proteins Market - Global Strategic Business Report: Sales Hit to $5.8 Billion by 2030 - Benchmark Thermo Fisher Scientific, Merck KGaA, Amgen, Bio-Techne and GenScript Biotech Amid Tariff Disruption

2026-09-30
Demand for biologics, targeted therapies and personalized medicine is rising, while AI-led protein design and scalable bioprocessing unlock new opportunities.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Recombinant Proteins Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global recombinant proteins market was valued at US$3.3 billion in 2024 and is projected to reach US$5.8 billion by 2030, expanding at a compound annual growth rate of 10.2%. Ma

Fetal Bovine Serum Market Outlook 2026-2035 - Featuring Profiles of Leading Companies Thermo Fisher Scientific, Merck KGaA, and Cytiva

2026-09-30
Fetal Bovine Serum Market Gains Momentum as Stem Cell Research, Vaccine Innovation and Advanced Therapies Drive Demand for High-Quality, Ethically Sourced ProductsDublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Fetal Bovine Serum Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. The global fetal bovine serum market was valued at USD 1.1 billion in 2025 and is projected to reach USD 2.3 billion by 2035, expanding

Thermo Fisher Scientific (TMO) Stock Seems Reasonable Following Its 47% Run

2026-09-29
Thermo Fisher Scientific has been a strong performer over the past year, and that kind of run naturally raises a pointed question for anyone looking at the stock today. Is the current share price aligned with the cash flows the business is expected to generate, or has sentiment moved ahead of the underlying economics? The stock has returned 47.4% over the past year, which puts real pressure on the question of whether the current valuation still lines up with the cash being produced and...

Thermo Fisher (TMO) Is Turning Innovation Into Recurring Revenue. Can Margins Follow?

2026-09-29
On September 23, Thermo Fisher Scientific Inc. (NYSE:TMO) announced the launch of the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to accelerate cell growth and protein production for CHO-K1 host lines used in biologics and biosimilars development. Offered in liquid and dry powder formats, the ready-to-use catalog panel enables […]

Will Thermo Fisher’s New cGMP CHO-K1 Panel and MRD Moves Change Thermo Fisher Scientific's (TMO) Narrative

2026-09-29
Earlier this month, Thermo Fisher Scientific announced several product and collaboration updates, including the cGMP-ready Gibco CHO-K1 Catalog Panel for bioprocessing, a reseller agreement to distribute Evosep’s Eno separation platform in proteomics workflows, and expanded involvement in molecular residual disease programs with Biodesix and Memorial Sloan Kettering. Together, these moves deepen Thermo Fisher’s role across biologics manufacturing, advanced proteomics, and ctDNA-based cancer...